Anti-PD-1/PD-L1免疫檢查點抑制劑的皮膚副作用

張綜顯 ； 張雲亭

《臨床醫學月刊》 87卷2期 (2021/02) Pp. 123-126

https://doi.org/10.6666/ClinMed.202102_87(2).0019

摘要

免疫檢查點抑制劑（immune checkpoint inhibitors）是近幾年來癌症治療的重大突破，其中anti-PD-1（anti-programmed cell death protein-1）與anti-PD-L1（anti-programmed cell death ligand-1）已成為許多癌症末期時的第一線治療藥物。然而，在達到療效的同時，這些藥物藥物也會引發免疫相關不良反應（immune-related adverse event, irAE），其中皮膚即為最容易發生irAE的器官。能早期識別並即時治療皮膚irAE十分重要，因其可遏止皮膚症狀惡化，並避免因延緩或終止anti-PD-1/PD-L1治療導致癌症進展。

關鍵字

抗細胞程式死亡受體-1（anti-programmed cell death protein-1, anti-PD-1） ； 抗細胞程式死亡配體-1（anti-programmed cell death ligand-1, anti-PD-L1） ； 免疫檢查點抑制劑（immune checkpoint inhibitor） ； 免疫相關不良反應（immune-related adverse event, irAE）

參考文獻

Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015;151:1206-12.

Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375-91.

Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 2016;22:886-94.

Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Current Opinion in Oncology 2016;28:1.

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.